Clinical Evaluation of Fractional Radiofrequency for the Treatment Acne Scarring

Acne Scars Clinical Trial

Official title:

Clinical Evaluation of the Safety and Performance of Fractional Radiofrequency for the Treatment and Reduction of Acne Scarring

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03821324
• Other study ID #: VI1118
• Status: Completed
• Phase: N/A
• Start date: December 11, 2018
• Est. completion date: October 3, 2019

Study information

• Verified date: March 2021
• Source: Venus Concept
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Prospective, single centre, evaluator-blind study of the safety and performance of fractional radiofrequency (RF) for the treatment and reduction of acne scarring. The study will evaluate the progress of 15 subjects requesting treatment of acne scarring. The study will involve three treatments on both sides of the face with 3-5 week intervals between each treatment. Subjects will be followed at 6 and 12 weeks after their last treatment. Analysis will be performed on all subjects who receive at least one treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: October 3, 2019
• Est. primary completion date: October 3, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 22 Years and older

Eligibility

Inclusion Criteria:

1. Healthy, male or female subjects over 21 years of age who are seeking treatment and reduction of their acne scarring.

2. Able to read, understand and voluntarily provide written Informed Consent.

3. Able and willing to comply with the treatment/follow-up schedule and requirements.

4. Women of child-bearing age are required to be using a reliable method of birth control at least 3 months prior to study enrollment and for the duration of the study and have a negative Urine Pregnancy test at baseline.

Exclusion Criteria:

1. Implantable defibrillators, cardiac pacemakers, and other metal implants

2. Subjects with any implantable metal device in the treatment area

3. Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body (e.g. cochlear implant).

4. Permanent implant in the treated area, such as metal plates and screws, or an injected chemical substance.

5. Current or history of any kind of cancer, or pre-malignant moles.

6. Severe concurrent conditions, such as cardiac disorders.

7. Pregnancy or intending to become pregnant during the study and nursing.

8. Impaired immune system due to immunosuppressive diseases, such as AIDS and HIV, or use of immunosuppressive medications.

9. History of diseases stimulated by heat, such as recurrent herpes simplex in the treatment area; may be enrolled only after a prophylactic regime has been followed for 2 weeks or longer prior to enrollment, or according to Investigator's discretion.

10. Poorly controlled endocrine disorders, such as diabetes.

11. Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash.

12. History of skin disorders, such as keloids, abnormal wound healing, as well as very dry and fragile skin.

13. History of bleeding coagulopathies, or use of anticoagulants (excluding daily aspirin).

14. Facial dermabrasion, facial resurfacing, or deep chemical peeling within the last three months, if face is treated.

15. Use of isotretinoin (Accutane®) or other systemic retinoids within six months or topical retinoids within three months prior to treatment; or as per physician's discretion.

16. Use of non-steroidal anti-inflammatory drugs (NSAIDS, e.g. ibuprofen-containing agents) one week before and after each treatment session.

17. Any surgical procedure in the treatment area within the last six months or before complete healing.

18. Treating over tattoo or permanent makeup.

19. Excessively tanned skin from sun, tanning beds or tanning creams within the last two weeks.

20. As per the practitioner's discretion, refrain from treating any condition which might make it unsafe for the patient.

Related Conditions & MeSH terms

• Acne Scars
• Cicatrix

Intervention

Device:
• Venus Viva
The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart. The left and right side of the face will be treated and assessed as independent sites, and the same applicator tip configuration will be used to treat both sides at all 3 treatment visits.

Locations

Country	Name	City	State
United States	Sadick Research Group	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Venus Concept

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Acne Scar Improvement	Change in acne scarring at 12 weeks post-treatment compared to baseline as assessed by blinded evaluators using photographs a 7-point Global Aesthetic Improvement Scale (GAIS) (ranges from -3 Very Much Worse to +3 Very Much Improved).	12 weeks post-final treatment (approximately Week 20)
Secondary	Subject Satisfaction	Subjects' assessment of satisfaction with the treatment using a 5-point Subject Satisfaction Scale (ranging from 0 Very Unsatisfied to 4 Very Satisfied) at 6 weeks and 12 weeks post-treatment.	12 weeks post-final treatment (approximately Week 20)
Secondary	Subject Scale - Visual Analog Scale for Pain	Subjects' assessment of discomfort and pain after treatments as measured by a 10 cm visual analog scale (VAS) with 0 being no pain and 10 being pain as bad as it can be. Each subject was asked to rate their pain after each of the 3 treatments. The result is the mean of each subject's mean VAS score.	Immediately post-treatment at each treatment (average of all 3 treatments)
Secondary	Treatment Tolerability	Subjects' assessment of treatment tolerability as measured by a 5-point scale ranging from 0 (Very Intolerable) to 4 (Very Tolerable).	Immediately post-treatment at each treatment (mean of the tolerability scores following each of the 3 treatments)